Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Clinical trial NCT01383759 · COMPLETED

Trial details

NCT number: NCT01383759
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Light Chain Deposition Disease (LCDD or MIDD)Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)Monoclonal Immunoglobulin Deposition Disease (MIDD)Amyloidosis

Start date: 2011-06-24
Primary completion: 2019-04-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.